GEN Exclusives

More »

GEN News Highlights

More »
Dec 12, 2007

BioWa and Lonza Will Pool Tools to Develop Enhanced Antibody Platform

  • BioWa and Lonza agreed to bring together their technologies to create a new antibody platform. BioWa’s Potelligent® and Lonza’s GS Gene Expression System™ and CHOK1SV cell line will be combined.

    The companies expects to generate a new platform that will produce more potent antibodies with greatly enhanced antibody-dependent cellular cytotoxicity (ADCC) in a high-yield mammalian expression system for industry-wide use.

    Under the terms of the agreement, the new Potelligent CHOK1SV cell line will be available for licensing as part of Lonza’s development services in combination with the firm’s GS Gene Expression System. The two companies will jointly market the new technology.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?